Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 10/20 | 0.52 |
| ▸ | NOS1 | P29475 | 10/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.52 |
| ▸ | NOS2 | P35228 | 5/20 | 0.52 |
| ▸ | HTR1D | P28221 | 10/20 | 0.46 |
| ▸ | HTR1B | P28222 | 10/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR1F | P30939 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263052 | 0.93 | NOS3 (0.46) | NOS3NOS1SLC6A2NOS2HTR1D | |
| SCHEMBL2914800 | 0.91 | SLC6A2 (0.47) | NOS3NOS1SLC6A2NOS2HTR1D | |
| SCHEMBL2908452 | 0.91 | SLC6A2 (0.47) | NOS3NOS1SLC6A2NOS2HTR1D | |
| SCHEMBL1122115 | 0.90 | NOS3 (0.64) | NOS3NOS1SLC6A2NOS2HTR1D | |
| SCHEMBL14178968 | 0.90 | NOS3 (0.64) | NOS3NOS1SLC6A2NOS2HTR1D | |
| SCHEMBL1122079 | 0.90 | NOS3 (0.49) | NOS3NOS1SLC6A2NOS2HTR1D | |
| SCHEMBL12305809 | 0.88 | NOS3 (0.48) | NOS3NOS1SLC6A2NOS2HTR1D | |
| SCHEMBL2919909 | 0.85 | SLC6A2 (0.45) | NOS3NOS1SLC6A2NOS2HTR1D | |
| SCHEMBL12857201 | 0.85 | NOS3 (0.52) | NOS3NOS1SLC6A2NOS2HTR1D | |
| SCHEMBL12305187 | 0.84 | NOS3 (0.50) | NOS3NOS1SLC6A2NOS2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | disclosed |
| EP-1883451-B1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC (CA) | 2009-05-21 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | SLC6A2, AANAT, NOS3 | NOS3 3/4885NOS1 5/4885SLC6A2 1/4885 |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885SLC6A2 920/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885SLC6A2 920/4885 |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885SLC6A2 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.